A prescription only creates value if the patient can actually start the therapy. Investors are now putting billions behind the infrastructure designed to make that happen, and pharmacists already understand the problems this new category is trying to solve.
On September 8, healthcare technology company Forus announced that it raised $150 million in Series C financing at a $3 billion valuation.
The funding round is impressive.
But the more important question for pharmacists is:
What problem is the market valuing at $3 billion?
Forus is building technology around the increasingly important space between:
Prescription written → treatment actually started
That includes benefits verification, prior authorizations, appeals, financial assistance, specialty pharmacy coordination, pharmacy routing, and patient communication.
In other words, this is not a company developing the next drug.
It is building infrastructure around getting existing therapies to the patients who need them.
And that should get pharmacists’ attention.
What exactly are investors valuing at $3 billion?
Forus is not discovering new medications.
It is not manufacturing medications.
It is not a dispensing pharmacy.
It is building technology around one of the most frustrating parts of modern medication use:
Everything that happens after the prescription is written but before the patient actually starts treatment.
That is a much bigger healthcare opportunity than it might sound.
Writing the prescription is not the same as starting the medication
A prescriber can select the right medication.
The evidence can support it.
The patient can agree to take it.
The prescription can be sent.
And the patient can still never receive the drug.
Why?
Prior authorization.
Insurance requirements.
Step therapy.
Missing documentation.
A denial.
An appeal.
A specialty pharmacy mandate.
A limited distribution network.
A financial assistance application.
An unaffordable copay.
A pharmacy routing problem.
A missing signature.
A patient who does not know what is happening.
Another portal.
Another fax.
Another phone call.
Another handoff.
This is the gap Forus is trying to automate.
Its platform works within provider workflows to support tasks including benefits verification, prior authorization submission, denial appeals, manufacturer program enrollment, financial assistance, pharmacy routing and patient communication. Forus says the platform can identify relevant information in clinical notes for prior authorizations, flag missing information, prepare appeal documentation for review, complete enrollment forms and identify an appropriate pharmacy or site of care based on payer requirements, manufacturer networks and patient or provider preferences.
And Forus uses a memorable way to describe what it is building:
Every prescription gets its own AI agent.
That should get the attention of pharmacists.
Because much of what these AI agents are being built to navigate is work pharmacy teams, specialty pharmacies, provider offices, medication access teams and patients have been wrestling with for years.
We have spent billions improving the drug. Now we are improving the path to the drug.
Think about how healthcare innovation traditionally gets discussed.
New molecule.
New mechanism.
New biologic.
New gene therapy.
New indication.
New clinical trial.
New precision medicine strategy.
And all of that progress matters.
But there is an uncomfortable reality.
A medication cannot improve a patient’s outcome if the patient never starts it.
Forus describes its mission around this exact problem. The company says modern medicine has advanced faster than the infrastructure required to move treatment through insurance, affordability and distribution. Its platform connects doctors, pharmacies, payers, patients and biopharma in an effort to move medications through that system more efficiently.
That is the larger story.
Scientific innovation created an enormous medication industry.
Now the complexity created around accessing those medications is helping create another industry alongside it.
Medication access is becoming infrastructure.
And investors appear to believe that infrastructure can be extremely valuable.
Follow the prescription after it leaves the doctor’s computer
This is where pharmacists should start looking at the medication journey differently.
We often think of the prescription as the beginning of pharmacy’s part of the process.
But take a high-cost specialty medication.
The prescription might travel through a much longer chain:
Clinical decision
↓
Prescription
↓
Benefits investigation
↓
Coverage requirements
↓
Prior authorization
↓
Additional documentation
↓
Approval or denial
↓
Appeal if needed
↓
Financial assistance
↓
Specialty network determination
↓
Pharmacy routing
↓
Patient communication
↓
Medication fulfillment
↓
Treatment initiation
Every one of those arrows represents an opportunity for delay.
Every delay is a workflow problem.
Every workflow problem creates administrative cost.
And some of those problems ultimately become medication-access problems for patients.
That is why the space between prescription written and treatment started is becoming so valuable.
Pharmacists know this workflow better than they may realize
Here is where I think this becomes particularly interesting for our profession.
Ask a pharmacist what prior authorization means and they probably do not need a definition.
Ask them about:
Refill too soon.
Product not covered.
Step therapy required.
Prior authorization required.
Specialty pharmacy required.
Quantity limits.
Formulary alternatives.
Manufacturer assistance.
Copay cards.
Coverage denials.
Prescriber outreach.
Missing diagnosis codes.
Pharmacy network restrictions.
Patients abandoning expensive prescriptions.
These are not abstract healthcare concepts to pharmacists.
They are Tuesday afternoon.
Pharmacists see the consequences when the infrastructure between prescribing and dispensing fails.
That domain knowledge matters.
Because if technology companies want to redesign medication access, somebody has to understand how medication access actually works.
This is what pharmacists should learn from the $3 billion valuation
The lesson is not:
“AI is taking over prior authorizations.”
That is too narrow.
The better lesson is:
There is tremendous value in solving the operational problems surrounding medication therapy.
That opens up an entirely different way to think about pharmacy careers.
Your value as a pharmacist does not have to exist only in knowing which medication should be used.
There is also value in understanding:
How the medication gets covered.
How it moves through the benefit.
What documentation supports approval.
Why claims fail.
How payer rules influence access.
How specialty networks function.
Where patients abandon therapy.
Which steps require clinical judgment.
Which steps are repetitive.
Which parts can be automated safely.
Which exceptions require a human.
How technology should fit into the workflow.
That is healthcare domain expertise.
And healthcare technology companies need domain expertise.
The medication access stack is becoming its own career ecosystem
This does not mean every pharmacist should go work for a medication-access startup.
It means pharmacists should recognize the broader category developing around them.
There are increasingly important problems at the intersection of:
Medication + insurance + technology + workflow + patient access
That can translate into work across several areas.
Medication access strategy
Understanding why patients struggle to start therapy and designing systems that reduce those barriers.
Specialty pharmacy operations
Managing the complex journey associated with high-cost and specialty therapies, including payer requirements, distribution limitations and patient support.
Healthcare product development
Helping product and engineering teams understand what actually happens after a prescription is written and translating messy real-world workflows into usable technology.
Clinical operations
Designing scalable processes that move patients from prescription to treatment while preserving appropriate clinical oversight.
Implementation
Taking a medication-access technology platform and successfully introducing it into physician practices, health systems, pharmacies or specialty workflows.
Payer and PBM strategy
Understanding coverage requirements, formulary design, utilization management and how those decisions affect medication access.
Market access and pharmaceutical services
Working around the systems through which therapies reach appropriate patients, including coverage, reimbursement, provider support and patient access programs.
AI evaluation and workflow governance
Determining where automation works, where exceptions occur, what information the system requires and where expert review needs to remain.
The titles will vary.
The underlying problem is the same:
How do we move the right medication from a clinical decision to an actual patient taking it?
A PharmD can be very useful in answering that question.
Look at what Forus is actually asking its technology to understand
Forus says each patient’s path can differ based on medical history, insurance coverage and financial circumstances.
Its AI agents may need to work across portals, documents, phone calls and faxes, interpret incomplete information and determine the next step in the access process.
This is an important point about AI in healthcare.
The opportunity is not simply:
Take paperwork and automate it.
Healthcare workflows are full of exceptions.
Different drug.
Different payer.
Different indication.
Different patient.
Different clinical history.
Different formulary.
Different specialty network.
Different documentation requirement.
Different affordability situation.
That complexity is precisely why healthcare has been difficult to automate.
And it is also why pharmacists who understand these exceptions can become valuable participants in building the technology.
Automation does not make domain knowledge irrelevant
It can make domain knowledge more important.
Imagine building a system that handles prior authorizations.
Someone needs to understand:
Which clinical information matters.
Where that information lives.
Which information is objective.
Which criteria require interpretation.
What happens if documentation conflicts.
What happens when the requested drug does not satisfy coverage criteria.
What happens after denial.
When an appeal is appropriate.
When another therapy might reasonably be considered.
When the provider needs to make a clinical decision.
What the technology should never decide independently.
That requires more than software knowledge.
It requires understanding the domain.
The strongest healthcare technology teams increasingly need people who can translate between the people building the system and the people actually using it.
Pharmacists can become those translators.
Look beyond the prescription itself
There is another career lesson here.
Pharmacy education understandably focuses heavily on medication knowledge.
What is the mechanism?
What is the dose?
What are the adverse effects?
What are the interactions?
What monitoring is required?
Those skills remain foundational.
But the modern medication ecosystem also rewards people who understand what happens around the medication.
Coverage.
Distribution.
Affordability.
Adherence.
Workflow.
Technology.
Patient communication.
Implementation.
Data.
Operations.
Business models.
You can think of it as two layers.
Layer 1: Medication Expertise
Which medication should the patient receive?
Then:
Layer 2: Medication Infrastructure
How does that medication actually reach the patient?
For pharmacists interested in nontraditional opportunities, Layer 2 is worth understanding.
Because entire companies are being built there.
Forus is also connecting more than physicians and pharmacies
The company’s ambitions extend beyond automating individual prior authorizations.
Forus says its network connects physicians, patients, pharmacies, payers and biopharma. As of its September 8 announcement, the company said its platform was being used by providers across all 50 states, reaching patients in 85% of U.S. residential ZIP codes, and that nine of the world’s 15 largest biopharmaceutical companies worked with Forus.
Forus has also begun partnering with organizations such as the American Gastroenterological Association to analyze and address medication-access barriers affecting patients with digestive diseases.
That starts revealing the bigger opportunity.
Once a platform sits between:
Prescriber.
Patient.
Payer.
Pharmacy.
Manufacturer.
it does not only process administrative work.
It can potentially provide visibility into where medication access breaks down.
That information itself becomes valuable.
Which therapies generate delays?
Where do denials occur?
What documentation is repeatedly missing?
Where does affordability become a barrier?
Which parts of the process create treatment delays?
Which patients never start therapy?
That is no longer just prior authorization software.
It starts looking like infrastructure around how medicine moves through healthcare.
That should change how pharmacists look at frustrating workflows
There is a mindset shift I want Pharmacy Unlocked readers to practice.
When something at work is incredibly annoying, do not only ask:
“Why is this process so terrible?”
Also ask:
“Why does this process exist, and what would it take to redesign it?”
That is the beginning of product thinking.
Take prior authorization.
A traditional response is:
“This takes too long.”
Product thinking goes further.
Where exactly does it take too long?
What information starts the process?
Who enters the information?
Where does the information come from?
Which steps repeat every time?
Which steps vary by payer?
Where does the process stop?
Why does it stop?
Who needs to intervene?
Which decisions require clinical judgment?
Which steps could software handle?
Where would automation create risk?
What would a better workflow look like?
Now you are no longer simply experiencing the problem.
You are analyzing the system.
That skill is extremely transferable.
Your Pharmacy Unlocked challenge this week
Choose one medication-access problem you encounter repeatedly.
It can be:
Prior authorization.
Step therapy.
A specialty pharmacy transfer.
A denied claim.
Copay assistance.
Patient assistance enrollment.
Finding a covered alternative.
A quantity limit.
A refill issue.
Prescriber documentation.
A medication the patient never picked up.
Then map it using five questions:
Where does it fail? → Who touches it? → What information is needed? → What decision requires expertise? → What could be automated?
1. Where does it fail?
Be specific.
Not:
“Prior authorizations are inefficient.”
Instead:
“We repeatedly wait three days because the office does not know which chart documentation the payer needs.”
Now you have an actual problem.
2. Who touches it?
Map every person or organization involved.
Patient.
Pharmacist.
Technician.
Prescriber.
Medical assistant.
Health plan.
PBM.
Specialty pharmacy.
Manufacturer hub.
Someone else?
Every additional handoff is worth examining.
3. What information is needed?
Diagnosis.
Previous therapies.
Dates of therapy.
Laboratory values.
Clinical response.
Contraindications.
Insurance information.
Formulary criteria.
Patient income.
Pharmacy network.
The information requirement often explains why the workflow becomes difficult.
4. What decision requires expertise?
This is critical.
Maybe gathering the documentation is repetitive.
But deciding whether the patient clinically meets criteria is not.
Maybe routing a prescription can be automated.
But determining whether a proposed therapeutic alternative is appropriate requires clinical judgment.
Separate:
Administrative work
from
Expert decision-making.
5. What could be automated?
Do not immediately say everything.
Maybe technology can:
Retrieve information.
Populate forms.
Track status.
Identify missing documentation.
Send reminders.
Route prescriptions.
Update patients.
Surface alternatives.
Then ask:
Where should a pharmacist still be involved?
That is the opportunity.
You just practiced product thinking
You do not need to code.
You do not need to launch a startup.
You do not need to call yourself a product manager.
You simply took a messy healthcare problem and broke it into:
Inputs.
Stakeholders.
Failure points.
Decisions.
Automation opportunities.
Human oversight.
That is how technology gets built.
And pharmacists are surrounded by healthcare problems worth solving every single day.
Stop looking at broken workflows only as inconveniences
They can also be career intelligence.
Every time you say:
“Why are we still doing it this way?”
pay attention.
Every time you fax something that should probably move electronically, pay attention.
Every time the same missing piece of information creates another delay, pay attention.
Every time a patient has no idea where their prescription went, pay attention.
Every time five people perform separate pieces of a process that nobody fully owns, pay attention.
Every time you manually copy information from one system into another, pay attention.
Those are not necessarily just frustrations.
They are signals.
Somewhere, an entrepreneur may be building a company around solving them.
And increasingly, healthcare organizations may need pharmacists who understand those problems well enough to help build the solution.
A $3 billion valuation is not proof that every medication-access startup will succeed
That distinction is important.
Private company valuations reflect investor expectations and negotiated financing terms. They do not guarantee future revenue, profitability or long-term success.
Forus still has to execute.
Its technology has to work reliably.
Its business model has to remain sustainable.
Providers and patients have to continue finding value in it.
Healthcare’s complicated network of payers, pharmacies, manufacturers and prescribers is not suddenly becoming simple.
But that is exactly why this funding round is worth paying attention to.
Investors led by Bain Capital Ventures just put another $150 million behind a company focused heavily on the infrastructure between prescribing and treatment initiation, valuing the business at $3 billion.
That tells us something about where people believe value can be created in healthcare.
The future of medication expertise is bigger than knowing the drug
Pharmacists should absolutely remain medication experts.
But the profession has an opportunity to expand what being a medication expert means.
Know the drug.
Know the patient.
Know the evidence.
And increasingly:
Know the system the medication has to travel through.
Understand why access fails.
Understand how coverage works.
Understand the workflow.
Understand where technology can help.
Understand where automation cannot replace judgment.
Understand how to translate clinical complexity into something a product team can build.
Because developing a remarkable medication only solves part of the problem.
The patient still has to receive it.
And if a company focused on solving that gap can command a $3 billion valuation, the infrastructure surrounding medications deserves a lot more attention from pharmacists.
The frustrating work we encounter every day may not simply be administrative noise.
It may be showing us exactly where some of healthcare’s next opportunities are being built.
Resources & Citations
1. Forus. “Building the AI Network for Medicine.” September 8, 2026.
Primary company announcement confirming the $150 million Series C financing at a $3 billion valuation, Bain Capital Ventures as lead investor, more than $300 million in total funding, Forus’ description of providing each prescription with its own AI agent, the company’s network model connecting physicians, patients, pharmacies, payers and biopharma, its reported national reach and its relationships with major biopharmaceutical companies.
Forus Series C announcement
2. MobiHealthNews. “Forus scores $150M at a $3B valuation.” September 8, 2026.
Independent reporting confirming the funding, valuation, approximate tripling of the company’s valuation in four months, and the medication-access functions of its platform, including benefits verification, prior authorizations, denial appeals, financial-assistance enrollment, specialty pharmacy coordination, pharmacy routing and patient communications.
MobiHealthNews coverage
3. Reuters. “AI healthcare platform Forus valued at $3 billion in latest funding round.” September 8, 2026.
Independent reporting confirming the $150 million financing, $3 billion valuation, roughly threefold valuation increase in approximately four months, national provider presence, reported patient reach, previous May financing and relationships with major biopharmaceutical companies.
Reuters coverage
4. Forus. “A Field Rep’s Guide to Forus.” January 6, 2026.
Primary source describing the medication-access workflow in detail, including electronic prescribing, clinical record extraction, prior authorization generation, payer submission, appeals, manufacturer program enrollment, pharmacy and site-of-care routing, patient updates, EHR integration and the distinction between automated administrative work and decisions requiring provider input.
Forus medication access workflow guide
5. Forus. “Building the Foundation for Modern Medicine.” May 12, 2026.
Primary source confirming the company’s previous $160 million financing, its rebrand from Tandem to Forus and its stated strategy of creating an AI-powered network connecting physicians, pharmacies, payers and biopharma around medication access.
Forus May 2026 announcement
6. Fierce Healthcare. “Forus secures $150M series C to grow AI-powered medication access platform.” September 8, 2026.
Independent healthcare-industry reporting confirming the Series C financing, $3 billion valuation, May financing and approximately threefold increase in valuation, along with the company’s focus on automating prescription access workflows.
Fierce Healthcare coverage
7. Forus and American Gastroenterological Association. “Forus and American Gastroenterological Association Announce Strategic Partnership to Improve Medication Access for GI Patients.” July 9, 2026.
Primary source describing the organizations’ collaboration around identifying and addressing barriers between prescribed therapies and patient access, as well as Forus’ medication-access functions across prior authorizations, appeals, financial assistance and pharmacy routing.
Forus and AGA partnership announcement
